DANCANN PHARMA A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0546 DKK | +29.38% |
|
-7.46% | +82.00% |
| Mar. 29 | Dancann Pharma Plans Up to DKK19 Million Rights Issue | MT |
| Feb. 28 | DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge | MT |
| Sales 2021 | 874K 127K | Sales 2022 | 7.19M 1.05M | Capitalization | 37.06M 5.39M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -1.6M | Net income 2022 | -16M -2.33M | EV / Sales 2021 | 192 x |
| Net cash position 2021 | 7.74M 1.12M | Net cash position 2022 | 10.75M 1.56M | EV / Sales 2022 | 3.66 x |
| P/E ratio 2021 |
-12.7
x | P/E ratio 2022 |
-2.31
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 14.49% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +29.38% | ||
| 1 week | -7.46% | ||
| 1 month | -24.17% | ||
| 3 months | +60.59% | ||
| 6 months | +18.70% | ||
| Current year | +82.00% |
1 week
0.04
0.06
1 month
0.040.08
Current year
0.010.13
1 year
0.010.37
3 years
0.017.06
5 years
0.017.06
10 years
0.017.06
| Managers | Title | Age | Since |
|---|---|---|---|
Jeppe Rasmussen
FOU | Founder | 29 | 18-03-19 |
| Director of Finance/CFO | 52 | 23-01-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carsten Trads
CHM | Chairman | 69 | - |
Jeppe Rasmussen
FOU | Founder | 29 | 18-03-19 |
| Director/Board Member | 40 | 21-04-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.0546 | +29.38% | 3,171,103 |
| 24-05-29 | 0.0422 | -18.53% | 1,194,658 |
| 24-05-28 | 0.0518 | -5.47% | 1,927,402 |
| 24-05-27 | 0.0548 | -7.12% | 1,950,376 |
End-of-day quote NORDIC GROWTH MARKET, May 30, 2024
More quotes
Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +82.00% | 1.32M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.09% | 21.96B | |
| -9.42% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- DANCAN Stock
